ICU Medical, Inc. (NASDAQ:ICUI) Holdings Lifted by Principal Financial Group Inc.

Principal Financial Group Inc. increased its stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 24.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 126,937 shares of the medical instruments supplier's stock after acquiring an additional 25,031 shares during the period. Principal Financial Group Inc. owned approximately 0.52% of ICU Medical worth $23,130,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Barclays PLC raised its holdings in shares of ICU Medical by 15.6% in the 3rd quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier's stock worth $10,790,000 after purchasing an additional 8,010 shares during the period. LMR Partners LLP acquired a new position in shares of ICU Medical during the 3rd quarter valued at $3,884,000. Savant Capital LLC purchased a new stake in ICU Medical during the 2nd quarter worth $431,000. First Eagle Investment Management LLC acquired a new stake in ICU Medical in the 2nd quarter valued at $3,479,000. Finally, MetLife Investment Management LLC raised its position in ICU Medical by 129.1% in the third quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier's stock valued at $2,258,000 after purchasing an additional 6,981 shares during the period. Institutional investors and hedge funds own 96.10% of the company's stock.

Insider Activity at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the company's stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at $17,973,261.12. This represents a 10.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Christian B. Voigtlander sold 1,962 shares of ICU Medical stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $169.08, for a total value of $331,734.96. The disclosure for this sale can be found here. Insiders have sold 40,364 shares of company stock valued at $6,869,878 over the last ninety days. Corporate insiders own 6.70% of the company's stock.

ICU Medical Stock Down 0.3 %

Shares of ICUI traded down $0.43 during trading on Thursday, reaching $156.46. The company's stock had a trading volume of 149,429 shares, compared to its average volume of 270,358. ICU Medical, Inc. has a twelve month low of $86.80 and a twelve month high of $196.26. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The company has a market cap of $3.83 billion, a price-to-earnings ratio of -34.24 and a beta of 0.62. The company has a fifty day moving average of $166.88 and a two-hundred day moving average of $154.05.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of ICU Medical in a research report on Wednesday, November 13th. Raymond James upped their price target on ICU Medical from $158.00 to $190.00 and gave the stock an "outperform" rating in a report on Thursday, September 12th. KeyCorp lifted their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the company an "overweight" rating in a research note on Wednesday, November 13th. Jefferies Financial Group raised shares of ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 target price on the stock in a research report on Wednesday, December 11th. Finally, StockNews.com raised shares of ICU Medical from a "hold" rating to a "buy" rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $199.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.